Chemokine modified peptide
By developing modified chemokine peptides containing specific amino acid sequences, we have solved the problem of high side effects or poor efficacy of existing cancer treatments and achieved effective inhibition and treatment of various cancers.
CN106279399AActive Publication Date: 2017-01-04RISE BIOPHARMACEUTICALS INC
3 Cites 2 Cited by
Patent Information
- Application Number
- CN201510301013.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2015-06-03
- Publication Date
- 2017-01-04
- Estimated Expiration
- 2035-06-03
AI Technical Summary
Technical Problem
Existing cancer treatments have side effects or are ineffective, making it difficult to detect early and effectively inhibit tumor growth.
Method used
Develop a modified chemokine peptide containing a specific amino acid sequence, including N'-glutamic acid-leucine-arginine and N'-proline-alanine-serine-glutamine- Phenylalanine characteristic sequence and substitution at the 17th amino acid to inhibit tumor growth and treat cancer.
Benefits of technology
The modified chemokine peptide can effectively inhibit the growth and angiogenesis of tumor cells, significantly reduce tumor volume and weight, improve microvessel density, has high affinity, and is suitable for the treatment of various types of cancer.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention relates to chemokine modified peptide. The chemokine modified peptide comprises an amino acid sequence, wherein the amino acid sequence is provided with (a) a characteristic sequence of N'-glutamic acid (E)-leucine (L)-arginine (R), (b) a characteristic sequence of N'-proline (P)-alanine (A)-serine (S)-glutamine (Q)-phenylalanine (F)-Cys<3>, and (c) a modified position; the characteristic sequence of the N'-glutamic acid (E)-leucine (L)-arginine (R) is located at an N end of the chemokine peptide; the characteristic sequence of the N'-proline (P)-alanine (A)-serine (S)-glutamine (Q)-phenylalanine (F)-Cys<3> is located at the third cysteine (Cys<3>) from the N end of the chemokine peptide; and the modified position is located at the seventeenth amino acid from the N end of the chemokine peptide. In addition, the chemokine modified peptide disclosed by the invention can be used for treating cancers and restraining tumor growth.
Need to check novelty before this filing date? Find Prior Art